{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiabwult5iahxjxjatsk7d6y5gvnpi6wk2gexcqmlqtdxybhnp5554",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgwarofwzf62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiccgdjvk2tqt4ou3xds55z7hzuut24usbfgzahz6lzzcibd5o2qu4"
    },
    "mimeType": "image/jpeg",
    "size": 46042
  },
  "path": "/2026/03/12/aldeyra-therapeutics-vertex-sarepta-therapeutics/?utm_campaign=rss",
  "publishedAt": "2026-03-12T10:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "drug development",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "How often do drugmakers complain about short sellers in SEC filings? And does it do any good?",
  "title": "STAT+: Is Aldeyra Therapeutics waving red flags with consequences?",
  "updatedAt": "2026-03-11T22:00:58.000Z"
}